RELATIVE VARIABILITY OF PROGRAF, NEORAL & CELLCEPT IN DIABETIC KIDNEY TXT PTS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。糖尿病患者通常患有消化问题，即胃轻瘫。这些消化问题会影响抗排斥药物的吸收。这些抗排斥药物吸收不良会导致移植肾排斥的风险增加。许多抗排斥药物的吸收，即Neoral， Prograf和Cellcept，在糖尿病移植患者中尚不完全清楚。本临床研究的目的是确定一种抗排斥药物治疗方案，使其更好地被糖尿病移植患者吸收。在这项研究中，受试者从Neoral切换到Prograf，并将继续使用强的松和Cellcept。受试者还接受6次每月12小时的抽血记录。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Diabetic patients typically suffer from digestive problems referred to as gastroparesis. These digestive problems can interfere with absorption of your anti-rejection medication. Poor absorption of these anti-rejection medications can lead to a higher risk of rejection of the transplanted kidney. The absorption of many anti-rejection drugs, namely Neoral, Prograf, and Cellcept, is not fully understood in diabetic transplant patients. The purpose of this clinical research study is to identify an anti-rejection medication regimen that is better absorbed by transplant patients with diabetes. In this study, subjects are switched from Neoral to Prograf and will continue to remain on prednisone and Cellcept. Subjects also undergo 6 monthly 12-hour blood draw profiles.